Alpha Tau Medical Ltd (DRTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.24B
Last updated: Nov 17, 2026 at 11:03 AM ET
Alpha Tau Medical Ltd (DRTS) Stock Forecast
Analysts expect Alpha Tau Medical (DRTS) to earn -$0.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $755000. Of 5 analysts, 4 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 80% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 3 | 60.0% |
| Hold | 1 | 20.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 1794.0%.
- Fiscal year ending Dec 31, 2026
- -$0.96
- EPS consensus, revenue $755000
- Fiscal year ending Dec 31, 2027
- -$0.54
- EPS consensus, revenue $14.30M
- Next report
- Nov 24, 2026
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.96 | -$1.08 to -$0.55 | 5 | $755000 | N/A | 2 |
| Dec 31, 2027 | -$0.54 | -$0.60 to -$0.50 | 5 | $14.30M | N/A | 3 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.16 | -$0.17 to -$0.16 | 6 | $629003 | N/A | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 7 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 4 |
| Fiscal year ending Dec 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.88.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.96 | -$0.96 | -$0.96 | -$0.96 | -$0.88 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.54 | -$0.53 | -$0.53 | -$0.53 | -$0.53 | N/A |
Frequently Asked Questions About DRTS
What is the DRTS stock forecast?
Consensus analyst estimates put Alpha Tau Medical's EPS at -$0.96 for the fiscal year ending Dec 31, 2026, on revenue of $755000. The consensus rating from 5 analysts is Buy.
How do analysts rate DRTS stock?
Of 5 analysts covering Alpha Tau Medical, 1 rates it Strong Buy, 3 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DRTS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.96, with estimates from -$1.08 to -$0.55 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.54, with estimates from -$0.60 to -$0.50 from 5 analysts.
What revenue do analysts expect from Alpha Tau Medical next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $755000. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $14.30M.
How many analysts cover DRTS?
5 analysts rate Alpha Tau Medical stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DRTS pages: Overview, Earnings, Forecast, Competitors